Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombotic Thrombocytopenic | 6 | 2018 | 12 | 1.050 |
Why?
|
| Platelet Activating Factor | 4 | 2007 | 14 | 0.830 |
Why?
|
| ADAM Proteins | 3 | 2012 | 13 | 0.790 |
Why?
|
| Apolipoprotein A-I | 5 | 2012 | 68 | 0.650 |
Why?
|
| Plasma Exchange | 2 | 2018 | 14 | 0.510 |
Why?
|
| Oxymorphone | 1 | 2014 | 9 | 0.470 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2014 | 8 | 0.470 |
Why?
|
| Mass Spectrometry | 3 | 2006 | 102 | 0.370 |
Why?
|
| Neutrophils | 4 | 2007 | 106 | 0.360 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2008 | 1 | 0.330 |
Why?
|
| Blood Coagulation Tests | 1 | 2008 | 7 | 0.320 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2008 | 3 | 0.320 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 94 | 0.310 |
Why?
|
| Myocardium | 1 | 2008 | 186 | 0.300 |
Why?
|
| Heart Diseases | 1 | 2008 | 116 | 0.290 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2006 | 2 | 0.280 |
Why?
|
| Blood Coagulation Disorders | 1 | 2006 | 13 | 0.280 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 39 | 0.280 |
Why?
|
| Hematoma | 1 | 2006 | 27 | 0.280 |
Why?
|
| Peptide Hydrolases | 1 | 2006 | 17 | 0.270 |
Why?
|
| Myocardial Infarction | 2 | 2008 | 475 | 0.270 |
Why?
|
| Clinical Chemistry Tests | 1 | 2004 | 1 | 0.250 |
Why?
|
| Humans | 23 | 2018 | 32005 | 0.240 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2004 | 9 | 0.240 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 14 | 0.240 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 11 | 0.240 |
Why?
|
| Thrombosis | 1 | 2004 | 73 | 0.230 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 247 | 0.220 |
Why?
|
| Cholesterol | 4 | 2012 | 252 | 0.200 |
Why?
|
| Membrane Microdomains | 2 | 2012 | 21 | 0.190 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2012 | 60 | 0.190 |
Why?
|
| Autoimmunity | 2 | 2010 | 32 | 0.170 |
Why?
|
| Lipoproteins, HDL | 2 | 2012 | 251 | 0.170 |
Why?
|
| Female | 12 | 2018 | 19959 | 0.170 |
Why?
|
| Dendritic Cells | 2 | 2016 | 59 | 0.150 |
Why?
|
| Male | 9 | 2014 | 19165 | 0.150 |
Why?
|
| Mixed Function Oxygenases | 2 | 2008 | 12 | 0.140 |
Why?
|
| Middle Aged | 7 | 2014 | 11817 | 0.140 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2016 | 9 | 0.140 |
Why?
|
| Melanoma, Experimental | 1 | 2016 | 11 | 0.140 |
Why?
|
| Diet, Atherogenic | 3 | 2011 | 62 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 24 | 0.140 |
Why?
|
| Obesity | 1 | 2003 | 1175 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 99 | 0.130 |
Why?
|
| T-Lymphocytes | 2 | 2009 | 124 | 0.130 |
Why?
|
| Dapsone | 1 | 2014 | 4 | 0.120 |
Why?
|
| Anemia, Hemolytic | 1 | 2014 | 7 | 0.120 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 21 | 0.120 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2014 | 27 | 0.120 |
Why?
|
| Atherosclerosis | 2 | 2011 | 766 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 6 | 2016 | 767 | 0.110 |
Why?
|
| Adult | 4 | 2014 | 9345 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 582 | 0.110 |
Why?
|
| Plasmapheresis | 1 | 2012 | 11 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 517 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 156 | 0.100 |
Why?
|
| Macrophages | 2 | 2010 | 191 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2012 | 71 | 0.100 |
Why?
|
| Immunosuppression | 1 | 2012 | 121 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2011 | 50 | 0.100 |
Why?
|
| Recurrence | 1 | 2012 | 263 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 54 | 0.090 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 16 | 0.090 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 23 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 35 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 240 | 0.090 |
Why?
|
| Mice | 6 | 2016 | 2484 | 0.090 |
Why?
|
| Plasmids | 2 | 2008 | 48 | 0.090 |
Why?
|
| Methods | 1 | 2008 | 11 | 0.080 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2008 | 3 | 0.080 |
Why?
|
| von Willebrand Factor | 1 | 2008 | 16 | 0.080 |
Why?
|
| Necrosis | 1 | 2008 | 53 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2008 | 51 | 0.080 |
Why?
|
| Automation | 1 | 2008 | 31 | 0.080 |
Why?
|
| Troponin I | 1 | 2008 | 22 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 2009 | 63 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 37 | 0.080 |
Why?
|
| Factor VII | 1 | 2008 | 3 | 0.080 |
Why?
|
| Acetyltransferases | 2 | 2005 | 2 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2008 | 19 | 0.080 |
Why?
|
| Risk Factors | 2 | 2008 | 3876 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 45 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2008 | 3509 | 0.080 |
Why?
|
| Lipids | 2 | 2010 | 232 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2005 | 36 | 0.070 |
Why?
|
| Animals | 8 | 2016 | 7541 | 0.070 |
Why?
|
| Echocardiography | 1 | 2008 | 159 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2005 | 135 | 0.070 |
Why?
|
| Copper | 1 | 2007 | 12 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2007 | 24 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2005 | 229 | 0.070 |
Why?
|
| Deuterium | 1 | 2007 | 9 | 0.070 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 14 | 0.070 |
Why?
|
| Isotope Labeling | 1 | 2007 | 16 | 0.070 |
Why?
|
| Calibration | 1 | 2007 | 28 | 0.070 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 33 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 28 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 166 | 0.070 |
Why?
|
| Young Adult | 1 | 2014 | 2636 | 0.070 |
Why?
|
| Antifibrinolytic Agents | 1 | 2006 | 16 | 0.070 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2006 | 7 | 0.070 |
Why?
|
| DNA Primers | 1 | 2006 | 91 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 62 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2006 | 87 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2006 | 87 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3306 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 762 | 0.070 |
Why?
|
| Base Sequence | 1 | 2006 | 252 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 285 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 37 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 359 | 0.070 |
Why?
|
| Vitamin K | 1 | 2005 | 9 | 0.060 |
Why?
|
| Factor IX | 1 | 2005 | 11 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2003 | 472 | 0.060 |
Why?
|
| Osmotic Pressure | 1 | 2005 | 10 | 0.060 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2005 | 12 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 66 | 0.060 |
Why?
|
| Glycerophospholipids | 1 | 2004 | 1 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 43 | 0.060 |
Why?
|
| Chromatography | 1 | 2004 | 4 | 0.060 |
Why?
|
| Lysophosphatidylcholines | 1 | 2004 | 3 | 0.060 |
Why?
|
| Thrombocytosis | 1 | 2004 | 1 | 0.060 |
Why?
|
| Thrombophilia | 1 | 2004 | 7 | 0.060 |
Why?
|
| Pyridines | 1 | 2005 | 76 | 0.060 |
Why?
|
| Catalysis | 1 | 2004 | 65 | 0.060 |
Why?
|
| Phenotype | 1 | 2006 | 632 | 0.060 |
Why?
|
| Imidazoles | 1 | 2005 | 91 | 0.060 |
Why?
|
| Factor VIII | 1 | 2004 | 25 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 105 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2004 | 289 | 0.060 |
Why?
|
| Time Factors | 2 | 2009 | 2149 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2016 | 185 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2005 | 231 | 0.050 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2002 | 2 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2003 | 293 | 0.050 |
Why?
|
| Receptors, Eicosanoid | 1 | 2002 | 3 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 61 | 0.050 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2002 | 50 | 0.050 |
Why?
|
| Factor V | 1 | 2002 | 7 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2002 | 34 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 49 | 0.050 |
Why?
|
| Continental Population Groups | 1 | 2003 | 237 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 91 | 0.050 |
Why?
|
| Sex Factors | 1 | 2003 | 663 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2002 | 211 | 0.050 |
Why?
|
| Lipoproteins, LDL | 2 | 2011 | 81 | 0.040 |
Why?
|
| Aorta | 2 | 2011 | 126 | 0.040 |
Why?
|
| Aged | 3 | 2008 | 10301 | 0.040 |
Why?
|
| Receptors, LDL | 2 | 2010 | 65 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 88 | 0.040 |
Why?
|
| Lymphocyte Count | 2 | 2010 | 24 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 1022 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2010 | 107 | 0.040 |
Why?
|
| Stroke | 1 | 2004 | 585 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 48 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2018 | 43 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 471 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2010 | 604 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 264 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2016 | 25 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2016 | 7 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 77 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 55 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 594 | 0.030 |
Why?
|
| Cell Line | 2 | 2008 | 435 | 0.030 |
Why?
|
| Sphingomyelins | 1 | 2012 | 7 | 0.030 |
Why?
|
| Ceramides | 1 | 2012 | 10 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2012 | 84 | 0.030 |
Why?
|
| Biological Transport | 1 | 2012 | 69 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2012 | 98 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2011 | 40 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 95 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 35 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 230 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 88 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 74 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2010 | 67 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 40 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 338 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2010 | 81 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 109 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 177 | 0.020 |
Why?
|
| Apolipoproteins | 1 | 2011 | 200 | 0.020 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 833 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 49 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 87 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 211 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 132 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 75 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 76 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 443 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 226 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 80 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 191 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 49 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 530 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2010 | 682 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2005 | 15 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 36 | 0.020 |
Why?
|
| Cricetinae | 1 | 2005 | 39 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2005 | 42 | 0.020 |
Why?
|
| Kidney | 1 | 2008 | 518 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 1595 | 0.010 |
Why?
|
| Benzoquinones | 1 | 2002 | 4 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 13 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2002 | 17 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2002 | 5 | 0.010 |
Why?
|
| Calcimycin | 1 | 2002 | 6 | 0.010 |
Why?
|
| Acyltransferases | 1 | 2002 | 16 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 36 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 43 | 0.010 |
Why?
|
| Phospholipases A | 1 | 2002 | 26 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2002 | 23 | 0.010 |
Why?
|
| Indoles | 1 | 2002 | 56 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 170 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 70 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2002 | 3 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 85 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2002 | 16 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 26 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 105 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 71 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2002 | 96 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 105 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 321 | 0.010 |
Why?
|
| Synapses | 1 | 2002 | 83 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 226 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 733 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 495 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 898 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 510 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 489 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 469 | 0.010 |
Why?
|